wjpmr, 2025, 11(8), 18-29

WORLD JOURNAL OF PHARMACEUTICAL AND MEDICAL RESEARCH

www.wjpmr.com

SJIF Impact Factor: 6.842

Review Article

ISSN (O): 2455-3301

ISSN (P): 3051-2557

BEYOND THE BARRIER: HARNESSING NANOTECHNOLOGY TO CNS DRUG DELIVERY SYSTEMS

Naga Harshitha[1]* and Tajuddin Shaik[2]

[1]Pharm-D 3rd Year Malla Reddy College of Pharmacy, Dhulapally, Secunderabad, Telangana.
[2]Assisstant Professor- Pharmacology Department Malla Reddy College of Pharmacy, Dhulapally, Secunderabad, Telangana.

***Corresponding Author: Naga Harshitha**

Pharm-D 3rd Year Malla Reddy College of Pharmacy, Dhulapally, Secunderabad, Telangana.

Article Received on 26/05/2025 **Article Revised on 17/06/2025** **Article Accepted on 07/07/2025**

ABSTRACT

Due to the very selective nature of the blood-brain barrier (BBB), medication administration to the central nervous system (CNS) is a significant task. Traditional pharmaceutical techniques frequently fail to achieve therapeutic concentrations in the brain, limiting the efficacy of treatments for neurological illnesses such Alzheimer's, Parkinson's, glioblastoma, and epilepsy. Recent advances in nanotechnology provide a breakthrough approach for overcoming this barrier and delivering medications with greater accuracy, efficacy, and safety. This study analyses the most recent developments in nanocarrier systems, including as liposomes, dendrimers, solid lipid nanoparticles, and polymeric micelles, which are intended to cross the BBB and target CNS regions. Surface modification methods, such as ligand conjugation and PEGylation, are emphasized as ways to improve BBB permeability and lower systemic toxicity. Furthermore, we investigate stimuli-responsive and biomimetic nanoparticles that adapt to the CNS milieu, allowing for controlled and targeted medication release. In this review, neurology and nanotechnology are combined to show how tailored Nano systems are enhancing CNS medication bioavailability and enabling individualized, non-invasive treatment. Finally, nanotechnology could transform CNS illness management and neurotherapeutics.

KEYWORDS FOR ABSTRACT (CNS DRUG DELIVERY WITH NANOTECHNOLOGY FOCUS)

1. Central Nervous System (CNS)
2. Blood–Brain Barrier (BBB)
3. Drug Delivery Systems
4. Nanocarriers
5. Neurotherapeutics
6. Stimuli-Responsive Nanoparticles
7. Biodegradable Nanomaterials
8. Focused Ultrasound (FUS)
9. CNS Disorders
10. Smart Drug Delivery

INTRODUCTION

The human brain is one of the most complicated and important organs in the body. The blood-brain barrier (BBB) is a unique and highly selective boundary that protects the brain's delicate environment. This specialized system is essential for maintaining central nervous system (CNS) homeostasis by protecting brain tissue from poisons, infections, and changes in blood composition. However, while the BBB is an important protective mechanism, it also poses substantial hurdles for therapeutic medication delivery to the brain.

Clinical Relevance and Challenges

While the BBB is necessary for brain protection, its selective nature presents difficulties in treating neurological illnesses. Many prospective medicinal compounds are unable to pass the barrier in effective amounts.

- **Neurodegenerative Diseases:** BBB malfunction has been linked to the advancement of illnesses such as Alzheimer's and Parkinson's.
- **Brain Tumors:** The BBB can obstruct the administration of chemotherapeutic medicines to brain tumors.

- **Infections and Inflammation:** Certain pathogens (such as meningitis-causing bacteria) and autoimmune reactions can impair the BBB.
- Overcoming the blood-brain barrier (BBB) and other central nervous system (CNS) medication delivery difficulties with nanotechnology requires a mix of targeted methods, nanocarrier engineering, and responsive delivery systems.



"Fig. 1"

3. Nano technologies

The Blood-Brain Barrier: A Double-Edged Sword

The brain's capillaries are lined with tightly packed endothelial cells that form the blood-brain barrier. By controlling what can enter and leave the central nervous system, these cells serve as gatekeepers. This barrier is necessary to keep infections and toxins out of the brain, but it also makes it more difficult to administer life-saving medications for diseases like multiple sclerosis, Alzheimer's, Parkinson's, brain tumors, and epilepsy.

Entering to Nanotechnologies

Materials that are manipulated at the nanoscale (1–100 nanometers) have special qualities that set them apart from their larger equivalents. This is known as nanotechnology. Nanocarriers can be made to target certain cells, encapsulate medications, and penetrate biological barriers like the blood-brain barrier.

Advantages of Nano technology in CNS Therapies

- Enhanced medication solubility and stability
- targeted delivery to damaged brain areas.
- Reduced side effects.
- Controlled and continuous release.
- Enhanced bioavailability.

4. Key Strategies and Technologies

I. Nanocarrier-Based Strategy

The following are the primary technologies utilized to transfer medications over the BBB:

1. Liposomes: These are biocompatible and biodegradable vesicles modified with ligands (e.g., transferrin, lactoferrin) to cross the BBB. They can encapsulate both hydrophilic and lipophilic medicines.

2. Solid Lipid Nanoparticles (SLNs): Improved stability and controlled release. Can transport lipophilic CNS drugs. Reduces toxicity from polymeric materials.

3. Polymeric Nanoparticles: PLGA, PEG, and chitosan-based systems. Controlled and sustained release. Surface modification for BBB penetration

4. Dendrimers: They are highly branching, tree-like polymers with high drug loading efficiency and functional groups for targeted delivery.

5. Nanoemulsions and Nanosuspensions: Improve CNS medication solubility. Easy to manufacture and scale.

II. Methods for BBB penetration

These strategies increase the possibility of nanoparticles penetrating the BBB.

1. Receptor-Mediated Transport (RMT): It involves the use of ligands (e.g., transferrin, insulin, low-density lipoproteins) that bind to receptors on BBB endothelial cells for transcytosis.

2. Adsorptive-Mediated Transcytosis (AMT): Positively charged surfaces interact with negatively charged BBB. Non-specific yet effective for some delivery systems

3. Carrier-Mediated Transport (CMT): CMT mimics endogenous substrates (e.g., glucose, amino acids) and requires precise targeting to prevent competition with natural ligands.

4. BBB disruption (temporary or controlled): Focused ultrasound (FUS): FUS using microbubbles. Hyperosmotic agents (such as mannitol). Limited clinical use due to safety issues.

III. Surface Modification and Targeting Approaches

1. PEGylation (Polyethylene Glycol Coating): Increases circulation time. Lowers immunological clearance. Enhances nanoparticle stability

2. Ligand Conjugation: Transferrin, folic acid, ApoE, and antibodies (e.g., anti-TfR). Target specific receptors on BBB or brain tumor cells.

3. Cell-Penetrating Peptides (CPPs): Allows direct translocation across cell membranes . Can be coupled with different nanoparticles

4. Biomimetic coatings: Uses cell membranes (e.g., red blood cells, leukocytes) to elude the immune system and target inflamed CNS regions.

IV. Stimulus-responsive and smart systems

1. pH-Responsive Nanocarriers: Release medications in acidic environments such as tumor locations or inflamed CNS regions.

2. Enzyme-Responsive Systems: * Respond to overexpressed enzymes in sick CNS tissues, such as matrix metalloproteinases.

3. Temperature or Ultrasound-Triggered Release: External triggers enable controlled and site-specific medication release.

4. Redox-Sensitive Nanocarriers: Use redox gradients in sick brain tissue for medication release.

V. Emerging Technologies

1. Exosome-Mediated Delivery: Natural vesicles that can pass the blood-brain barrier * Can deliver therapeutic cargo

2. Magnetic Nanoparticles: Targeted CNS locations using external magnetic fields * Used for imaging and diagnosis (theranostics).

3. CRISPR/Cas9 Nanodelivery: Used for gene editing or therapy in CNS disorders * Can be delivered by lipids, polymers, or viral/non-viral nanocarriers.

4. Hydrogel-Based Depot devices

Injectable devices that establish depots near CNS tissues Enables prolonged, localized drug release

VI. Challenges to Address

Nanomaterial toxicity and biocompatibility

Scalability and reproducibility for clinical-grade production

Long-term safety and immunogenicity

Regulatory approvals and standardization.



"Fig:2".

4. BBB is a significant barrier to CNS drug delivery

1. Structure and Function: Endothelial cells, astrocyte end-feet, and compose the BBB, which is selective and closely regulated. Its major function is to shield the brain from toxins and infections in the bloodstream while enabling critical nutrients to pass through.

2. Drug Exclusion: The BBB prevents around 98% of small-molecule medicines and 100% of big molecules, including peptides, antibodies, and gene therapies, from crossing unassisted. It restricts hydrophilic and high-molecular-weight substances by tight junctions and active efflux pumps, such as P-glycoprotein.

3. Clinical Impact: Reduces treatment options for neurodegenerative illnesses, brain tumors, epilepsy, and stroke. Many potentially beneficial medications fail in clinical trials due to low CNS penetration.

Diseases Affected by BBB Constraints

- Alzheimer's Disease



"Fig:3".

- Parkinson's Disease



"Fig:4".

- **Glioblastoma**



"Fig:5"

- Epilepsy
- Multiple Sclerosis
- CNS Infections and Neuroinflammation

5. Key Obstacle of the Blood–Brain Barrier (BBB)
Individual Permeability The BBB is highly restrictive, allowing only:

➢ Small (<400 Da), lipophilic molecules
➢ Through the use of carrier proteins, specific nutrients like glucose and amino acids
➢ Very few large molecules or biologics

What is it mean for Drug Delivery?
"Table: 1"

Barrier Feature	Impact on Drug Delivery
Tight junctions between endothelial cells	Blocks paracellular transport of drugs
Efflux pumps (e.g., P-glycoprotein)	Actively remove drugs from the CNS
Enzymatic degradation	Destroys drugs before reaching brain tissue
Low pinocytosis	Minimal vesicle-based drug uptake
Lack of nonspecific pores	Restricts passage of hydrophilic or large molecules

Result
When taken systemically, more than 98% of small-molecule medicines and nearly 100% of big biologics do not reach effective concentrations in the brain.

Common CNS Drug Delivery Challenges
➢ Alzheimer's: BBB prevents antibodies and enzymes from reaching plaques.
➢ Parkinson's: Dopamine does not penetrate the BBB directly.
➢ Brain tumours: Chemotherapy frequently fails due to insufficient penetration.
➢ Epilepsy: Drug-resistant forms associated with BBB-related efflux mechanisms

Conclusion: The BBB's protective function poses a significant therapeutic challenge. Innovative delivery techniques, such as nanocarriers, receptor-mediated transport, focused ultrasound, and cell-penetrating peptides, are being developed to circumvent or exploit the BBB for CNS medication administration.

6. New Technologies in CNS Drug Delivery Systems (2024–2025)

1. Exosome-Based Drug Delivery
➢ it is Cell-derived, nano-sized extracellular vesicles.
➢ Advantages:
○ Crosses the blood-brain barrier naturally
○ Is biocompatible and non-immunogenic
○ Can transport RNA, proteins, or tiny medicines Applications: Alzheimer's, Parkinson's, glioblastoma, and stroke.



"Fig: 7".

2. Focused ultrasound (FUS) with microbubbles
➢ It works with Low-intensity ultrasound and gas microbubbles are used to temporarily open the blood-brain barrier in particular brain regions.
➢ Benefits:
○ Allows for localized medication delivery
○ Non-invasive and reproducible Clinical
○ Trials: Ongoing for Alzheimer's and brain cancers.



"Fig: 8"

3. CRISPR/Case gene editing using nanocarriers

- ➢ Nanoparticles transport CRISPR components to change genes in the brain, targeting Huntington's disease, gliomas, and hereditary epilepsy.
- ➢ Carriers: lipid nanoparticles, gold nanoclusters, and viral vectors

4. Magnetic nanoparticles (MNPs) for targeted delivery

- ➢ Mechanism: External magnetic fields are used to guide the brain to certain locations.
- ➢ Use cases include glioblastoma and stroke therapy.
- ➢ Theranostic Potential: Combines therapy and imaging (MRI-visible).

5. Stimuli-Responsive Nanocarriers

- ➢ Types:
  - ○ pH-sensitive - Release medicine in acidic tumor/inflammation zones
  - ○ Redox-sensitive - Respond to oxidative stress in CNS disorder.
  - ○ Ultrasound/heat-triggered - Controlled release at target site
  - ○ Benefits: On-demand, targeted therapy.

6. Hydrogel-Based Depot Systems

- ➢ Hydrogels for prolonged, localized drug release are injectable and biodegradable.
- ➢ Applications include post-surgical glioma therapy and Parkinson's management.
- ➢ Innovation: Smart hydrogels respond to changes in the CNS microenvironment.

7. Artificial Intelligence (AI)-Driven Delivery Platforms

a. Usage

i. Predict nanoparticle BBB penetration

ii. Optimize drug formulations and release profiles

iii. Design targeted nanocarriers using big data

Example: Deep learning models used to predict CNS-targeting ligands

8. Trojan Horse Nanoparticles

a. Concept: Use receptor-mediated transcytosis across BBB to mimic natural ligands like transferrin or insulin.

b. Benefit: Targeted, non-invasive CNS entry.

c. Examples of drugs include antibodies, siRNA, and peptides.

9. CPPs (Cell Penetrating Peptides) and protein carriers enable direct transport of medicines or genes across cell membranes.

a. Use: Increasing CNS absorption of biologics, antisense oligonucleotides (ASOs), and mRNA.

10. Lipid–Polymer Hybrid Nanoparticles

a. Technology: Combines the stability of polymers and the bioavailability of lipids

b. Used For: Delivering poorly soluble or unstable CNS drugs

c. Customization: Can be PEGylated or ligand-modified for BBB crossing.

"Table: 2"

Technology	Function	CNS Application	Status
Exosome Delivery	Natural nanoscale vesicle transport	Neurodegenerative diseases	Clinical/preclinical
Focused Ultrasound (FUS)	BBB opening with ultrasound	Alzheimer's, brain tumors	Trials ongoing
CRISPR Nanodelivery	Gene editing in the brain	Genetic disorders, glioma	Early trials
Magnetic Nanoparticles	External magnetic targeting	Brain cancer, stroke	Experimental
Smart Nanocarriers	Stimuli-triggered drug release	Tumors, inflamed regions	In development
Hydrogel Depots	Long-term, local release	Post-tumor resection, epilepsy	Prototype stage
AI-Guided Drug Design	Carrier optimization	General CNS drug delivery	Emerging
Trojan Horse Nanoparticles	Receptor-mediated BBB crossing	Alzheimer's, MS	Advanced preclinical
CPPs & Protein Carriers	Enhance intracellular transport	Gene therapies	Developing
Lipid–Polymer Nanoparticles	Hybrid delivery for solubility/stability	Epilepsy, Parkinson's	Preclinical

7. Emerging Opportunities in CNS Drug Delivery

1. Next-generation nanocarriers

a. Opportunity: Create highly specialized, biodegradable, and personalized nanocarriers for CNS diseases.

b. What's Driving It: Polymer science advancements, AI-guided carrier optimization, and surface engineering.

c. Impact: Enables targeted treatment of malignancies, neuroinflammation, and degenerative areas.

2. Gene Therapy And RNA-Based Therapeutics

a. Opportunity: Deliver CRISPR, mRNA, siRNA, and ASOs across the BBB to silence or repair genes.

b. Diseases targeted include Huntington's, ALS, glioblastoma, and uncommon pediatric encephalopathies.

c. Emerging Markets: CNS genetic treatment pipelines are fast growing in biotech firms.

3. Personalized CNS Drug Delivery

a. Opportunity: Tailoring medicine delivery systems according to a patient's

b. BBB permeability

c. Genomic profile

d. Disease stage or brain region

e. Enablers: AI, wearable biosensors, and liquid biopsy of brain-derived exosomes

4. Non-invasive Neuromodulated Delivery

a. Opportunity: Use of external fields (magnetic, ultrasonic, or electrical) to direct or stimulate medication release.

b. Techniques: Focused Ultrasound (FUS), transcranial magnetic stimulation (TMS), optogenetics + medication combination.

c. Advantage: Minimizes the requirement for surgery or systemic exposure.

5. Smart Hydrogels and Injectable Depots

Opportunity: Create CNS-specific drug delivery devices that respond to brain signals or inflammatory levels.

Use Case: Glioma Resection Sites, Epileptic Foci, or Neuroinflammatory Zones

6. Biomimetic and Trojan Horse Approaches

Opportunity: Use biology, such as exosomes or ligand-conjugated proteins, to "sneak" pharmaceuticals through the BBB.

Trends include the development of modified vesicles and antibody-drug conjugates to treat neurodegeneration and brain malignancies.

7. Integration of AI and Computational Neuroscience

a. Machine learning can predict BBB transport efficiency, model disease-drug interactions, and design delivery vehicles before physical synthesis.

b. Startups and pharmaceutical companies are investing heavily in digital twins for the brain.

8. Theranostics: Drug and Diagnostic Systems.

a. Opportunity: Combine medication administration with real-time monitoring (e.g., MRI-visible nanoparticles and glucose-sensitive devices).

b. Use: Monitor treatment response in brain tumors or Parkinson's disease development.

9. Global expansion and unmet needs

a. Opportunity: CNS illnesses (Alzheimer's, mental health, neuroinfections) are on the rise worldwide, particularly in aging populations.

b. Asia, South America, and Africa are emerging markets for accessible, non-invasive CNS medicines.

10. Regulatory and Commercial Pathways

a. Opportunities: It include orphan drug and fast-track designations for CNS medicines with innovative delivery methods.

b. Support: The FDA and EMA are providing paths for neuro-targeted nanomedicines.

"Table: 3"

Opportunity	Enabler	Potential Impact
Smart nanocarriers	AI + material science	Precision targeting in the brain
Gene therapy delivery	CRISPR, mRNA, siRNA	Long-term CNS disease modification
Personalized delivery systems	Biomarkers + AI	Tailored treatment with fewer side effects
Neuromodulated systems	FUS, magnetic fields	Non-invasive and local drug activation
Theranostics	Imaging + therapy nanoparticles	Real-time feedback and treatment
Global CNS access	Portable, non-invasive systems	Expanding care to underserved populations

8. Various types of Nanotechnologies

1. Nano-Particles: These are tiny particles which are in the size between 1 and 100 nanometers.

Examples:

- Gold Nanoparticle: it is used in imaging, cancer therapy
- Silver Nanoparticle: It is used for coating antibacterial.
- Iron-Oxide Nanoparticle: It is used in MRI contrast agents.

Applications:

- Drug delivery
- Biosensors
- Antimicrobial coatings

2. Nanotubes: These are the Cylindrical Carbonic molecules with nanoscale diameter.

➢ Single walled or multi-walled tubes of carbon atoms are said to be carbon nano-tubes.

Applications:

- Electronics
- Tissue engineering
- Brain and nerve repair
- Drug transport systems

3. Nanoshells: These are the Nanoparticles with a metal shell (usually gold) and a dielectric core (e.g., silica)

Applications:

- Cancer therapy (thermal ablation)
- Imaging
- Drug delivery

4. Nanowires: These are the wires with a diameter on the nanoscale.

Applications:

- Biosensors
- Nanoelectronics
- Photovoltaics

5. **Quantomdots:** Semiconductor nanoparticles that give off light at certain wavelengths based on their size.

Applications:
- Medical imaging
- Targeted drug delivery
- Displays and TVs

6. **Dendrimers:** These are the molecules which are highly branched and tree-like synthetic.

Applications:
- Drug delivery (can carry multiple drugs at once)
- Gene therapy
- Imaging

7. **Liposomes and micelles:** Nanoscale vesicles composed of lipid bilayers (liposomes) or surfactants (micelles).

Applications:
- Carry drugs across cell membranes or biological barriers
- Cancer drug delivery
- CNS drug delivery (as in your project)

8. **Nanocomposites:** These are the materials which combine nanoparticles with bulk materials to enhance properties.

Applications:
- Bone implants
- Coatings with improved strength or conductivity
- Packaging materials

9. **Nanorobots (nanobots):** These are experimental or Hypothetical nanoscale machines.

Applications:
- Perform precise surgery at the cellular level
- Clear clogged arteries
- Deliver drugs directly to targeted cells

10. **Exosomes (Biogenic Nanoparticles):** It is a naturally occurring nanovesicles which is secreted by cells.

Applications
- Drug delivery (especially for CNS)
- Biomarker detection
- Cell-to-cell

9. How is it more Effective

1. **Crossing the Blood Brain Barrier (BBB)**
- The BBB is responsible for blocking 98% of medications, which means that the majority of drugs are unable to enter the brain.
- Nanotechnology can help by mimicking natural chemicals or employing ligands to pass the blood-brain barrier through receptor-mediated transport.
- Some nanosystems (such as exosomes or PEGylated liposomes) can travel through or bypass the blood-brain barrier without disturbing it.
- **More effective:** Delivers previously unusable medications due to the BBB.

2. **Target Delivery**
- Drugs diffuse throughout the body, resulting in adverse effects and inefficiency.
- Nanotechnology helps Nanocarriers to be designed to target specific brain cells or disease areas (for example, tumours and plaques in Alzheimer's).
- They limit exposure to healthy tissues.
- More effective: Higher medication concentration at the target means less negative effects.

3. **Controlled and Sustained Release**
- Traditional challenge: Drugs may decay quickly or require frequent doses.
- Nanotechnology enables delayed and consistent medication delivery through nanocarriers.
- Some systems in the brain respond to stimuli such as changes in pH or temperature.
- More effective: Longer-lasting benefits and higher patient compliance.

4. **Improved Drug Solubility and Stability**
- Traditional Challenge: Many CNS medicines have low water solubility or instability in the body.
- Nanotechnology helps: Nanocarriers encapsulate medications and protect them from degradation.
- Improves absorption and bioavailability.
- More effective: Uses medications that could not be administered otherwise.

5. **Non-invasive Delivery routes**
- Traditional Challenge: Injecting medications directly into the CNS is intrusive and hazardous.
- Nanotechnology applications include nasal sprays, oral capsules, and transdermal patches.
- Examples include nose-to-brain delivery, which totally bypasses the BBB.
- Improved effectiveness, safety, and patient comfort.

6. **Combination Therapy and Theranostics**
- Traditional challenge: Difficulty diagnosing and treating on a single platform.
- Nanotechnology: Theranostics refers to the use of nanoparticles for both imaging and therapy.
- Useful for brain tumours and neurological disorders.
- Improved effectiveness with early detection and tailored therapy in one shot.

"Table: 4"

Feature	Traditional Methods	Nanotechnology
BBB Penetration	Poor	Excellent
Targeting	Low	High
Side Effects	High	Low
Dosage Control	Weak	Strong
Stability	Low	High
Patient Comfort	Invasive	Often non-invasive

10. CONCLUSION

Nanotechnology represents a dramatic breakthrough in addressing one of medicine's most enduring challenges: successfully delivering medications to the brain. Nanotechnological platforms are redefining the future of CNS therapies by allowing for accurate, targeted, and sustained drug release across the blood-brain barrier.

From nanoparticles and liposomes to dendrimers and exosomes, these nanoscale carriers have distinct benefits such as increased bioavailability, fewer side effects, and the capacity to overcome traditional restrictions of drug solubility and invasiveness. Furthermore, improved strategies such as receptor-mediated targeting and nose-to-brain administration make nanotechnology both novel and practical for patients.

Although regulatory and safety issues persist, continuous research and clinical advances indicate that nanotechnology is not only feasible, but a necessary progression in neuropharmacology. With ongoing investment and interdisciplinary collaboration, nanotechnology has the potential to open up new therapeutic options for hitherto untreatable brain illnesses.

In essence, nanotechnology propels us past the barrier, towards a future where effective, precise, and non-invasive brain treatment is the new standard of care.

11. ACKNOWLEDGEMENT

With great appreciation, I would like to thank everyone who helped and advised me during this endeavour. First and foremost, I want to express my gratitude to Tajuddin Shaik, who served as my project mentor, for their unwavering support, knowledgeable advice, and insightful comments that significantly influenced the scope and focus of my study.

12. REFERENCES

1. Saraiva, C., Praça, C., Ferreira, R., Santos, T., Ferreira, L., & Bernardino, L. *Nanoparticle-mediated brain drug delivery: Overcoming blood–brain barrier to treat neurodegenerative diseases.* Journal of Controlled Release, 2016; 235: 34–47. https://doi.org/10.1016/j.jconrel.2016.05.044
2. Pardridge, W. M. *Blood-brain barrier and delivery of protein and gene therapeutics to brain.* Frontiers in Aging Neuroscience, 2020; 11: 373. https://doi.org/10.3389/fnagi.2019.00373
3. Abbott, N. J., Patabendige, A. A., Dolman, D. E., Yusof, S. R., & Begley, D. J. *Structure and function of the blood–brain barrier.* Neurobiology of Disease, 2010; 37(1): 13–25. https://doi.org/10.1016/j.nbd.2009.07.030
4. Tiwari, G., Tiwari, R., Sriwastawa, B., Bhati, L., Pandey, S., Pandey, P., & Bannerjee, S. K. *Drug delivery systems: An updated review.* International Journal of Pharmaceutical Investigation, 2012; 2(1): 2–11. https://doi.org/10.4103/2230-973X.96920
5. Yang, T., Martin, P., Fogarty, B., Brown, A., Schurman, K., Phipps, R., & Yin, V. P. *Exosome delivered anticancer drugs across the blood–brain barrier for brain cancer therapy in Danio rerio.* Pharmaceutical Research, 2015; 32(6): 2003–2014. https://doi.org/10.1007/s11095-014-1593-y
6. Pulicherla, K. K. & Verma, A. *Drug Delivery and Translational Research*, 2019; 9(4): 888–902.
7. Wong, H. L. et al. *Current Pharmaceutical Design*, 2012; 18(3): 358–375.
8. Chadwick, R. et al. *Neuroethics and the Policy Landscape*. Cambridge Quarterly of Healthcare Ethics, 2014; 23(2): 164–176.
9. A. Manuja, B. Kumar, R. Kumar, D. Chhabra, M. Ghosh, M. Manuja, B. Brar, Y. Pal, B. N. Tripathi and M. Prasad, *Toxicol. Rep.*, 2021; 8: 1970—1978.
10. R. D. Brohi, L. Wang, H. S. Talpur, D. Wu, F. A. Khan, D. Bhattarai, Z.-U. Rehman, F. Farmanullah and L.-J. Huo, *Front. Pharmacol.*, 2017; 8: 606.
11. Brangwynne, C. P., Mitchison, T. J. & Hyman, A. A. Active liquid-like behavior of nucleoli determines their size and shape in *Xenopus laevis* oocytes. *Proc. Natl Acad. Sci. USA.*, 2011; 108: 4334–4339.
12. Patel, T., Zhou, J., Piepmeier, J. M., & Saltzman, W. M. *Polymeric nanoparticles for drug delivery to the central nervous system.* Advanced Drug Delivery Reviews, 2012; 64(7): 701–705. https://doi.org/10.1016/j.addr.2011.12.006
13. Patel, M. M., & Patel, B. M. *Crossing the blood–brain barrier: Recent advances in drug delivery to the brain.* CNS Drugs, 2017; 31: 109–133. https://doi.org/10.1007/s40263-017-0402-5
14. Zhang, Y., & Wang, F. *CRISPR/Cas systems for CNS diseases: Delivery strategies and potential applications.* CNS Neuroscience & Therapeutics, 2021; 27(8): 837–849. https://doi.org/10.1111/cns.13631
15. Van der Meel, R., Sulheim, E., Shi, Y., Kiessling, F., Mulder, W. J., & Lammers, T. *Smart cancer nanomedicine.* Nature Nanotechnology, 2019; 14:

1007–1017. https://doi.org/10.1038/s41565-019-0567-y
16. Beauchamp, T. L., & Childress, J. F. *Principles of Biomedical Ethics* (8th ed.). Oxford University Press. Core framework for informed consent, justice, beneficence, and non-maleficence, 2019.
17. Kimmelman, J., & Hyun, I. *Ethical considerations for CNS gene therapy trials.* Nature Reviews Neurology, 2020; 16: 462–472. https://doi.org/10.1038/s41582-020-0381-y
18. FDA (2023). *Drug products, including biological products, that contain nanomaterials – Guidance for Industry.* https://www.fda.gov/media/157812/download
19. EMA (2020). *Reflection paper on nanotechnology-based medicinal products for human use.* https://www.ema.europa.eu/en/documents/scientific-guideline/reflection-paper-nanotechnology-based-medicinal-products-human-use_en.pdf
20. NIH RAC Guidelines (2021). *NIH guidelines for research involving recombinant or synthetic nucleic acid molecules.* https://osp.od.nih.gov/biotechnology/nih-guidelines/
21. World Health Organization (WHO). (2022). *Ethics and governance of artificial intelligence for health.* https://www.who.int/publications/i/item/9789240029200
22. ICMR (India). (2017). *National Ethical Guidelines for Biomedical and Health Research Involving Human Participants.* https://ethics.ncdirindia.org//asset/pdf/ICMR_National_Ethical_Guidelines.pdf
23. Pardridge, W. M. (2012). *Drug transport across the blood-brain barrier*. Journal of Cerebral Blood Flow & Metabolism, 32(11): 1959–1972. https://doi.org/10.1038/jcbfm.2012.126
24. Tiwari, G. et al. (2012). *Drug delivery systems: An updated review*. International Journal of Pharmaceutical Investigation, 2(1): 2–11. https://doi.org/10.4103/2230-973X.96920
25. Saraiva, C. et al. (2016). *Nanoparticle-mediated brain drug delivery: Overcoming blood–brain barrier to treat neurodegenerative diseases*. Journal of Controlled Release, 235: 34–47. https://doi.org/10.1016/j.jconrel.2016.05.044
26. Misra, A., et al. (2003). *Drug delivery to the central nervous system: a review*. Journal of Pharmacy and Pharmaceutical Sciences, 6(2): 252–273. https://pubmed.ncbi.nlm.nih.gov/12935451
27. Bhaskar, S. et al. (2010). *Multifunctional nanocarriers for diagnostics, drug delivery and targeted treatment across blood-brain barrier: Perspectives on tracking and neuroimaging*. Particle and Fibre Toxicology, 7: 3. https://doi.org/10.1186/1743-8977-7-3
28. Kumar, A. et al. (2020). *Exosomes as emerging drug delivery systems for the treatment of brain disorders – A review*. International Journal of Molecular Sciences, 21(17): 6386. https://doi.org/10.3390/ijms21176386
29. Yadav, R., et al. (2021). *Nanocarriers for CNS drug delivery: current status and future perspective*. Artificial Cells, Nanomedicine, and Biotechnology, 49(1): 748–765. https://doi.org/10.1080/21691401.2021.1906171
30. Kreuter, J. (2014). *Drug delivery to the central nervous system by polymeric nanoparticles: What do we know?* Advanced Drug Delivery Reviews, 71: 2–14. https://doi.org/10.1016/j.addr.2013.08.008
31. Patel, T., Zhou, J., Piepmeier, J. M., & Saltzman, W. M. (2012). *Polymeric nanoparticles for drug delivery to the central nervous system*. Advanced Drug Delivery Reviews, 64(7): 701–705. https://doi.org/10.1016/j.addr.2011.12.006
32. Morris, M. C., Depollier, J., Mery, J., Heitz, F., & Divita, G. (2001). *A peptide carrier for the delivery of biologically active proteins into mammalian cells*. Nature Biotechnology, 19: 1173–1176. https://doi.org/10.1038/nbt1201-1173
33. Khan, A. R., et al. (2018). *Recent advances in surface modification of polymeric nanoparticles for brain targeting: A systematic review*. International Journal of Pharmaceutics, 553(1-2): 8–21. https://doi.org/10.1016/j.ijpharm.2018.10.034
34. Xin, H., et al. (2011). *Angiopep-conjugated poly(ethylene glycol)-co-poly(ε-caprolactone) nanoparticles as dual-targeting drug delivery system for brain glioma*. Biomaterials, 32(18): 4293–4305. https://doi.org/10.1016/j.biomaterials.2011.02.048
35. Tosi, G., et al. (2010). *Nanomedicine for brain delivery: Targeting and overcoming the blood-brain barrier*. Nanomedicine: Nanotechnology, Biology and Medicine, 6(3): 423–436. https://doi.org/10.1016/j.nano.2010.02.002
36. Nance, E., et al. (2014). *A dense poly(ethylene glycol) coating improves penetration of large polymeric nanoparticles within brain tissue*. Science Translational Medicine, 6(238): 238ra76. https://doi.org/10.1126/scitranslmed.3008873
37. Alavi, M., & Karimi, N. (2022). *Exosome-based delivery systems: Recent advances and future outlook in CNS disorders*. Journal of Drug Delivery Science and Technology, 71: 103261. https://doi.org/10.1016/j.jddst.2022.103261
38. Zhou, Q., Shao, S., Wang, J., Xu, C., Xiang, J., Piao, Y., & Tang, J. (2015). *Enzyme-activated nanoprobe for noninvasive imaging of tumor-related protease activity in living subjects*. ACS Nano, 9(3): 2702–2711. https://doi.org/10.1021/nn506374p *Relevance*: Demonstrates diagnostic potential of nanoparticles in tracking enzyme activity related to brain tumors.
39. Bhaskar, S., Tian, F., Stoeger, T., Kreyling, W., de la Fuente, J. M., Grazú, V., Borm, P., Estrada, G., & Nel, A. (2010). *Multifunctional nanocarriers for diagnostics, drug delivery and targeted treatment across blood–brain barrier: perspectives on tracking and neuroimaging*. Particle and Fibre Toxicology, 7: 3. https://doi.org/10.1186/1743-8977-7-3 *Relevance*: Covers theranostic

nanocarriers with focus on brain barrier penetration and real-time imaging.

40. Xie, J., Lee, S., & Chen, X. (2010). *Nanoparticle-based theranostic agents*. Advanced Drug Delivery Reviews, 62(11): 1064–1079. https://doi.org/10.1016/j.addr.2010.07.009 *Relevance*: Discusses dual-function nanoparticles that combine therapy and diagnostics — important in CNS tumors and neurodegenerative diseases.